猪群疫病mRNA疫苗研究进展

doi:10.16431/j.cnki.1671-7236.2025.09.031

摘要/Abstract

摘要： mRNA疫苗是将编码目的蛋白或多肽的mRNA大分子传递至细胞中，经翻译后产生相应抗原蛋白，诱导机体产生免疫应答，以达到免疫预防目的和效果的疫苗。目前，鉴于传统疫苗不能完全满足防疫需求，mRNA疫苗凭借其研发周期短、安全性高及免疫效力强等特点，已成为重大动物疫病防控的主要研究方向之一，有效的mRNA疫苗可减少猪病的发生和传播。笔者对mRNA疫苗的类型及结构、关键技术及已报道的mRNA疫苗在猪流行性腹泻、口蹄疫、猪繁殖与呼吸综合征、非洲猪瘟、猪伪狂犬病、猪流感等猪病领域的研究进行总结，展望mRNA疫苗在猪病防控、疫苗研发领域的应用，以期为猪群疫病mRNA疫苗的研制及开发提供参考。

关键词: mRNA疫苗; 免疫; 预防; 猪病

Abstract: mRNA vaccine,which encodes the target protein or polypeptide antigens,can be delivered to cells for translation to induce an immune response against pathogens.Given the urgent need to prevent and control swine diseases,traditional vaccines can’t fully meet the needs of epidemic prevention.With short development time,high safety and strong immune efficacy,mRNA vaccines have become one of the main research directions for the prevention and control of animal diseases.Effective mRNA vaccines can reduce the incidence and spread of swine diseases.The authors summarised the types and structures of mRNA vaccines,key technologies and research progress of mRNA vaccines for porcine epidemic diarrhea,foot-and-mouth disease,porcine reproductive and respiratory syndrome,African swine fever,porcine pseudorabies,swine influenza and other swine diseases.The application of mRNA vaccines in the prevention and control of swine diseases was further prospected to provide a reference for the development and production of mRNA vaccines for swine diseases.

Key words: mRNA vaccine; immunization; prevention; swine diseases

中图分类号:

S859.79^＋7

殷靖淇, 沙洲, 张海光, 崔进, 郑辉, 董雅琴, 魏荣, 古少鹏, 尼博. 猪群疫病mRNA疫苗研究进展[J]. 中国畜牧兽医, 2025, 52(9): 4346-4357.

YIN Jingqi, SHA Zhou, ZHANG Haiguang, CUI Jin, ZHENG Hui, DONG Yaqin, WEI Rong, GU Shaopeng, NI Bo. Research Progress of mRNA Vaccine for Swine Diseases[J]. China Animal Husbandry & Veterinary Medicine, 2025, 52(9): 4346-4357.

参考文献

[1] WOLFF J A,MALONE R W,WILLIAMS P,et al.Direct gene transfer into mouse muscle in vivo[J]. Science (New York, NY),1990,247(4949 Pt 1):1465-1468.
[2] SHARIF N,ALZAHRANI K J,AHMED S N,et al.Efficacy,immunogenicity and safety of COVID-19 vaccines:A systematic review and Meta-analysis[J].Frontiers in Immunology,2021,12:714170.
[3] ANAND P,STAHEL V P.Correction to:The safety of COVID-19 mRNA vaccines:A review[J].Patient Safety in Surgery,2021,15(1):22.
[4] WANG Y S,KUMARI M,CHEN G H,et al.mRNA-based vaccines and therapeutics:An in-depth survey of current and upcoming clinical applications[J].Journal of Biomedical Science,2023,30(1):84.
[5] 王子健,陈颖钰,胡长敏,等.我国兽用诊断试剂产业现状与未来趋势[J].生物技术进展,2021,11(4):471-475. WANG Z J，CHEN Y Y，HU C M,et al.Development status and perspective of veterinary diagnostic industry in China[J]. Current Biotechnology,2021,11(4):471-475.(in Chinese)
[6] GUO X,LIU D,HUANG Y,et al.Revolutionizing viral disease vaccination:The promising clinical advancements of non-replicating mRNA vaccines[J].Virology Journal,2023,20(1):64.
[7] CHAUDHARY N,WEISSMAN D,WHITEHEAD K A.mRNA vaccines for infectious diseases:Principles,delivery and clinical translation[J].Nature Reviews Drug Discovery,2021,20(11):817-838.
[8] YU M Z,WANG N N,ZHU J Q,et al.The clinical progress and challenges of mRNA vaccines[J].Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology,2023,15(5):e1894.
[9] ROHNER E,YANG R,FOO K S,et al.Unlocking the promise of mRNA therapeutics[J].Nature Biotechnology,2022,40(11):1586-1600.
[10] KWON H,KIM M,SEO Y,et al.Emergence of synthetic mRNA:In vitro synthesis of mRNA and its applications in regenerative medicine[J]. Biomaterials,2018,156:172-193.
[11] MARTIN S A,PAOLETTI E,MOSS B.Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions[J]. The Journal of Biological Chemistry,1975,250(24):9322-9329.
[12] MEI Y,WANG X.RNA modification in mRNA cancer vaccines[J].Clinical and Experimental Medicine,2023,23(6):1917-1931.
[13] VAIDYANATHAN S,AZIZIAN K T,HAQUE A,et al.Uridine depletion and chemical modification increase Cas9 mRNA activity and reduce immunogenicity without HPLC purification[J].Molecular Therapy Nucleic Acids,2018,12:530-542.
[14] GOSS D J,KLEIMAN F E.Poly(A) binding proteins:Are they all created equal?[J].Wiley Interdisciplinary Reviews RNA,2013,4(2):167-179.
[15] WAHLE E,RÜEGSEGGER U.3'-end processing of pre-mRNA in eukaryotes[J].FEMS Microbiology Reviews,1999,23(3):277-295.
[16] OH S,KESSLER J A.Design,assembly,production,and transfection of synthetic modified mRNA[J].Methods (San Diego, Calif),2018,133:29-43.
[17] LIMA S A,CHIPMAN L B,NICHOLSON A L,et al.Short Poly(A) tails are a conserved feature of highly expressed genes[J].Nature Structural & Molecular Biology,2017,24(12):1057-1063.
[18] SUBTELNY A O,EICHHORN S W,CHEN G R,et al.Poly(A)-tail profiling reveals an embryonic switch in translational control[J].Nature,2014,508(7494):66-71.
[19] ELANGO N,ELANGO S,SHIVSHANKAR P,et al.Optimized transfection of mRNA transcribed from a d(A/T)100 tail-containing vector[J].Biochemical and Biophysical Research Communications,2005,330(3):958-966.
[20] TANG T T L,PASSMORE L A.Recognition of Poly(A) RNA through its intrinsic helical structure[J].Cold Spring Harbor Symposia on Quantitative Biology,2019,84:21-30.
[21] QIU L,JING Q,LI Y,et al.RNA modification:Mechanisms and therapeutic targets[J].Molecular Biomedicine,2023,4(1):25.
[22] 蔚丹,马云龙,万方,等.mRNA疫苗的研究及应用进展[J].生物技术进展,2023,13(4):492-498. YU D,MA Y L,WAN F,et al.Advances on research and application of mRNA vaccines[J] Current Biotechnology,2023,13(4):492-498.(in Chinese)
[23] FERDOWS B E,PATEL D N,CHEN W,et al.RNA cancer nanomedicine:Nanotechnology-mediated RNA therapy[J].Nanoscale,2022,14(12):4448-4455.
[24] SAHIN U,KARIKÓ K,TÜRECI Ö.mRNA-based therapeutics—Developing a new class of drugs[J].Nature Reviews Drug Discovery,2014,13(10):759-780.
[25] LOOMIS K H,LINDSAY K E,ZURLA C,et al.In vitro transcribed mRNA vaccines with programmable stimulation of innate immunity[J].Bioconjugate Chemistry,2018,29(9):3072-3083.
[26] LI M,LI Y,LI S,et al.The nano delivery systems and applications of mRNA[J].European Journal of Medicinal Chemistry,2022,227:113910.
[27] KNUDSON C J,ALVES-PEIXOTO P,MURAMATSU H,et al.Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 T cells against a lethal viral infection[J].Molecular Therapy,2021,29(9):2769-2781.
[28] RABAAN A A,MUTAIR A A,HAJISSA K,et al.A comprehensive review on the current vaccines and their efficacies to combat SARS-CoV-2 variants[J].Vaccines,2022,10(10):1655.
[29] 孙伟伦,周悌强,杨海银,等.脂质纳米颗粒递送mRNA在疾病防治中的应用[J].生物化学与生物物理进展,2024,51(10):2677-2693. SUN W L,ZHOU T Q,YANG H Y,et al.The application of lipid nanoparticle-delivered mRNA in disease prevention and treatment[J] Progress in Biochemistry and Biophysics,2024,51(10):2677-2693.(in Chinese)
[30] BARBIERI B D,PEELER D J,SAMNUAN K,et al.The role of helper lipids in optimising nanoparticle formulations of self-amplifying RNA [J].Journal of Controlled Release,2024,374:280-292.
[31] SAUNDERS K O,PARDI N,PARKS R,et al.Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates[J].NPJ Vaccines,2021,6(1):50.
[32] PARDI N,PARKHOUSE K,KIRKPATRICK E,et al.Nucleoside-modified mRNA immunization elicits Influenza virus hemagglutinin stalk-specific antibodies[J].Nature Communications,2018,9(1):3361.
[33] RICHNER J M,HIMANSU S,DOWD K A,et al.Modified mRNA vaccines protect against Zika virus infection[J]. Cell,2017,168(6):1114-25.e10.
[34] DILLIARD S A,SIEGWART D J.Passive,active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs[J].Nature Reviews Materials,2023,8(4):282-300.
[35] ZHANG J,CHEN H,CHEN J.Colostrum-derived exosome based system:The next-generation nucleic acid delivery system with enhanced biosafety?[J].Molecular Therapy Nucleic Acids,2022,30:449-450.
[36] GRETZ J E,KALDJIAN E P,ANDERSON A O,et al.Sophisticated strategies for information encounter in the lymph node:The reticular network as a conduit of soluble information and a highway for cell traffic[J].Journal of Immunology (Baltimore,Md:1950),1996,157(2):495-499.
[37] CHEN J,YE Z,HUANG C,et al.Lipid nanoparticle-mediated lymph node-targeting delivery of mRNA cancer vaccine elicits robust CD8⁺ T cell response[J].Proceedings of the National Academy of Sciences of the United States of America,2022,119(34):e2207841119.
[38] ZHAO X,CHEN J,QIU M,et al.Imidazole-based synthetic lipidoids for in vivo mRNA delivery into primary T lymphocytes[J].Angewandte Chemie (International ed.in English),2020,59(45):20083-20089.
[39] RAMISHETTI S,HAZAN-HALEVY I,PALAKURI R,et al.A combinatorial library of lipid nanoparticles for RNA delivery to leukocytes[J].Advanced Materials (Deerfield Beach, Fla),2020,32(12):e1906128.
[40] LI M,LI Y,PENG K,et al.Engineering intranasal mRNA vaccines to enhance lymph node trafficking and immune responses[J].Acta Biomaterialia,2017,64:237-248.
[41] ROOZEN G V T,PRINS M L M,PRINS C,et al.Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine:Safety and immunogenicity of a fractional booster dose[J].Clinical Microbiology and Infection,2024,30(7):930-936.
[42] VANDER STRAETEN A,SARMADI M,DARISTOTLE J L,et al.A microneedle vaccine printer for thermostable COVID-19 mRNA vaccines[J].Nature Biotechnology,2024,42(3):510-517.
[43] WANG J,MA L,CHEN Y,et al.Immunogenicity and effectiveness of an mRNA therapeutic vaccine for HPV-related malignancies[J].Life Science Alliance,2024,7(6):e202302448.
[44] QIU Y,MAN R C H,LIAO Q,et al.Effective mRNA pulmonary delivery by dry powder formulation of PEGylated synthetic KL4 peptide[J].Journal of Controlled Release,2019,314:102-115.
[45] 楚电峰,于晓璐,孙化露,等.mRNA技术在动物疫病疫苗中的研究进展[J].中国动物检疫,2024,41(1):52-59. CHU D F,YU X L,SUN H L,et al.Research progress on mRNA technology in development of animal vaccines[J].China Animal Health Inspection,2024,41(1):52-59.(in Chinese)
[46] 刘晨阳,朱增勇,辛翔飞,等.国际生猪产业发展趋势特征及经验镜鉴[J].中国农业科技导报,2024,26(6):1-10. LIU C Y,ZHU Z Y,XIN X F,et al.Tendency characteristics and empirical references on development of international hog industry[J].Journal of Agricultural Science and Technology,2024,26(6):1-10.(in Chinese)
[47] 郭思杰.猪流行性腹泻基因工程疫苗的研制与应用[D].长沙:湖南农业大学,2022. GUO S J.Development and application of genetically engineered vaccine for porcine epidemic diarrhea[D].Changsha:Hunan Agricultural University,2022.(in Chinese)
[48] LIU X,ZHANG Q,ZHANG L,et al.A newly isolated Chinese virulent genotype GⅡb Porcine epidemic diarrhea virus strain:Biological characteristics,pathogenicity and immune protective effects as an inactivated vaccine candidate[J].Virus Research,2019,259:18-27.
[49] 杨利敏,王俊虹,徐明国,等.猪流行性腹泻mRNA疫苗的制备与免疫原性评价[J].生物工程学报,2023,39(7):2624-2633. YANG L M,WANG J H,XU M G,et al.Preparation and immunogenicity evaluation of mRNA vaccine against porcine epidemic diarrhea[J].Chinese Journal of Biotechnology,2023,39(7):2624-2633.(in Chinese)
[50] ZHAO Y,FAN B,SONG X,et al.PEDV-spike-protein-expressing mRNA vaccine protects piglets against PEDV challenge[J].mBio,2024,15(2):e0295823.
[51] WOO P C,LAU S K,HUANG Y,et al.Coronavirus diversity,phylogeny and interspecies jumping[J].Experimental Biology and Medicine (Maywood),2009,234(10):1117-1127.
[52] KNIGHT-JONES T J,ROBINSON L,CHARLESTON B,et al.Global foot-and-mouth disease research update and gap analysis:2-epidemiology,wildlife and economics[J]. Transboundary and Emerging Diseases,2016,63 Suppl 1:14-29.
[53] MARTÍNEZ-SALAS E,FRANCISCO-VELILLA R,FERNANDEZ-CHAMORRO J,et al.Picornavirus IRES elements:RNA structure and host protein interactions[J].Virus Research,2015,206:62-73.
[54] LORENZO G,RODRÍGUEZ-PULIDO M,LÓPEZ-GIL E,et al.Protection against Rift Valley fever virus infection in mice upon administration of interferon-inducing RNA transcripts from the FMDV genome[J].Antiviral Research,2014,109:64-67.
[55] RODRÍGUEZ-PULIDO M,BORREGO B,SOBRINO F,et al.RNA structural domains in noncoding regions of the Foot-and-mouth disease virus genome trigger innate immunity in porcine cells and mice[J].Journal of Virology,2011,85(13):6492-6501.
[56] RODRÍGUEZ-PULIDO M,SOBRINO F,BORREGO B,et al.Inoculation of newborn mice with non-coding regions of Foot-and-mouth disease virus RNA can induce a rapid,solid and wide-range protection against viral infection[J].Antiviral Research,2011,92(3):500-504.
[57] RODRÍGUEZ-PULIDO M,POLO M,BORREGO B,et al.Use of Foot-and-mouth disease virus non-coding synthetic RNAs as vaccine adjuvants[J].Methods in Molecular Biology,2022,2465:125-135.
[58] RODRÍGUEZ-PULIDO M,CALVO-PINILLA E,POLO M,et al.Non-coding RNAs derived from the Foot-and-mouth disease virus genome trigger broad antiviral activity against Coronaviruses[J].Frontiers in Immunology,2023,14:1166725.
[59] 董金杰,王会宝,王凡,等.基于猪口蹄疫O型病毒结构蛋白VP1基因的mRNA疫苗制备及免疫活性研究[J].农业生物技术学报,2022,30(6):1219-1227. DONG J J,WANG H B,WANG F,et al.Preparation and immunogenicity studies on mRNA vaccine based on VP1 gene of porcine Foot-and-mouth disease type O virus[J].Journal of Agricultural Biotechnology,2022,30(6):1219-1227.(in Chinese)
[60] WU Z,CHANG T,WANG D,et al.Genomic surveillance and evolutionary dynamics of type 2 Porcine reproductive and respiratory syndrome virus in China spanning the African swine fever outbreak[J].Virus Evolution,2024,10(1):veae016.
[61] ZHANG H,LUO Q,HE Y,et al.Research progress on the development of porcine reproductive and respiratory syndrome vaccines[J].Veterinary Sciences,2023,10(8):491.
[62] LE T,SUN C,CHANG J,et al.mRNA vaccine development for emerging animal and zoonotic diseases[J].Viruses,2022,14(2):401.
[63] CHANG Y H,LIN M W,CHIEN M C,et al.Polyplex nanomicelle delivery of self-amplifying RNA vaccine[J].Journal of Controlled Release,2021,338:694-704.
[64] ZHOU L,WUBSHET A K,ZHANG J,et al.The mRNA vaccine expressing single and fused structural proteins of porcine reproductive and respiratory syndrome induces strong cellular and humoral immune responses in BALB/c mice[J].Viruses,2024,16(4):544.
[65] 天康制药有限公司.用于预防猪繁殖与呼吸综合征的mRNA疫苗及制备方法[P].中国专利:202210697798,2022-09-09. TECON PHARMACEUTICAL CO.,LTD.mRNA vaccine for prevention of porcine reproductive and respiratory syndrome and its preparation method[P].Chinese Patent:202210697798,2022-09-09.(in Chinese)
[66] WANG T,SUN Y,QIU H J.African swine fever:An unprecedented disaster and challenge to China[J].Infectious Diseases of Poverty,2018,7(1):111.
[67] LIU J,LIU B,SHAN B,et al.Prevalence of African swine fever in China,2018-2019[J].Journal of Medical Virology,2020,92(8):1023-1034.
[68] GE S,LI J,FAN X,et al.Molecular characterization of African swine fever virus,China,2018[J].Emerging Infectious Diseases,2018,24(11):2131-2133.
[69] LIU Q,MA B,QIAN N,et al.Structure of the African swine fever virus major capsid protein p72[J].Cell Research,2019,29(11):953-955.
[70] 孙文强.ASFV特异性T细胞表位的筛选以及SARS-CoV-2 mRNA疫苗的研究[D].南宁:广西大学,2022. SUN W Q.Determination of ASFV-specific T cell epitopes and development of SARS-CoV-2 mRNA vaccine[D].Nanning:Guangxi University,2022.(in Chinese)
[71] 绵阳市游仙区创新科技产业技术研究院.治疗和/或预防非洲猪瘟病毒的疫苗及其制备方法[P].中国专利:202111162615，2021-09-30. MIANYANG YOUXIAN DISTRICT INNOVATION TECHNOLOGY INDUSTRY TECHNOLOGY RESEARCH INSTITUTE.Vaccines for the treatment and/or prevention of African swine fever virus and their preparation methods[P].Chinese Patent: 202111162615，2021-09-30.(in Chinese)
[72] MOISE L,GUTIÉRREZ A H,KHAN S,et al.New immunoinformatics tools for swine:Designing epitope-driven vaccines,predicting vaccine efficacy,and making vaccines on demand[J].Frontiers in Immunology,2020,11:563362.
[73] POMERANZ L E,REYNOLDS A E,HENGARTNER C J.Molecular biology of Pseudorabies virus:Impact on neurovirology and veterinary medicine[J].Microbiology and Molecular Biology Reviews,2005,69(3):462-500.
[74] ZHENG H H,JIN Y,HOU C Y,et al.Seroprevalence investigation and genetic analysis of Pseudorabies virus within pig populations in Henan province of China during 2018-2019[J].Infection, Genetics and Evolution,2021,92:104835.
[75] LIU Q,KUANG Y,LI Y,et al.The epidemiology and variation in Pseudorabies virus:A continuing challenge to pigs and humans[J].Viruses,2022,14(7):1463.
[76] JIANG C,MA Z,BAI J,et al.Comparison of the protective efficacy between the candidate vaccine ZJ01R carrying gE/gI/TK deletion and three commercial vaccines against an emerging Pseudorabies virus variant[J].Veterinary Microbiology,2023,276:109623.
[77] WONG G,LU J,ZHANG W,et al.Pseudorabies virus:A neglected zoonotic pathogen in humans[J].Emerging Microbes & Infections,2019,8(1):150-154.
[78] JIANG Z,ZHU L,CAI Y,et al.Immunogenicity and protective efficacy induced by an mRNA vaccine encoding gD antigen against Pseudorabies virus infection[J].Veterinary Microbiology,2020,251:108886.
[79] MA W.Swine influenza virus:Current status and challenge[J].Virus Research,2020,288:198118.
[80] VOGEL A B,LAMBERT L,KINNEAR E,et al.Self-amplifying RNA vaccines give equivalent protection against influenza to mRNA vaccines but at much lower doses[J].Molecular Therapy,2018,26(2):446-455.
[81] LEE I T,NACHBAGAUER R,ENSZ D,et al.Safety and immunogenicity of a phase 1/2 randomized clinical trial of a quadrivalent,mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults:Interim analysis[J].Nature Communications,2023,14(1):3631.
[82] XU S,ZHANG B,YAO J,et al.A new H9 Influenza virus mRNA vaccine elicits robust protective immunity against infection[J].Vaccine,2023,41(18):2905-2913.
[83] RCHEULISHVILI N,PAPUKASHVILI D,LIU C,et al.Promising strategy for developing mRNA-based universal Influenza virus vaccine for human population,poultry,and pigs-focus on the bigger picture[J].Frontiers in Immunology,2022,13:1025884.
[84] RCHEULISHVILI N,MAO J,PAPUKASHVILI D,et al.Designing multi-epitope mRNA construct as a universal influenza vaccine candidate for future epidemic/pandemic preparedness[J].International Journal of Biological Macromolecules,2023,226:885-899.